Beihai Biotech, with the slogan "Putting Patients First, Innovation for All," is a prominent biopharmaceutical company founded in 2008. The company is dedicated to revolutionizing healthcare through innovative therapeutics. It boasts two cutting-edge technology platforms: Precision Delivery Technology (PDT) platform, which enables precise delivery of therapeutics while maximizing efficacy and minimizing side effects, and the Peptide-Drug Conjugate (PDC) platform, which combines peptides and small molecule drugs for advanced drug development.
Having a pipeline of 10 promising drug candidates covering diverse therapeutic indications including Oncology and Pain, Beihai Biotech's most advanced asset is BH009, branded docetaxel with a much better safety profile and efficacy. It is in the approval stage with the US FDA via the 505B2 route and is expected to gain approval soon. The company has obtained over 30 patents in major markets worldwide, demonstrating its dedication to pioneering drug development.
Beihai Biotech believes in the power of scientific innovation and remains steadfast in developing breakthrough therapeutic drugs that are safe, effective, and urgently needed in clinical practice. The company's goal is to provide better treatment options for patients worldwide. It is driven by the clinical value its therapies offer and is committed to bringing these therapies to patients in need.
The company recently received a Series C investment on 14 December 2023, with participation from Hengguan Investment and GAINS Investment Corp. Beihai Biotech's dedication to scientific innovation and patient-centric approach positions it as a promising venture for investors looking to make an impact in the biopharma, biotechnology, and pharmaceutical industries. For further inquiries or information, interested parties are encouraged to contact Beihai Biotech as they strive to create a healthier future.
